AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Semler Scientific Class Action Lawsuit Filed Over Alleged False Claims Act Violations
ByAinvest
Friday, Aug 29, 2025 5:16 pm ET1min read
A class action lawsuit has been filed against Semler Scientific, Inc. (NASDAQ: SMLR) for allegedly failing to disclose investigations into violations of the False Claims Act. The lawsuit claims that defendants failed to disclose a material investigation by the US Department of Justice while discussing possible violations in hypothetical terms. The company revealed the investigation in February 2025 and later settled with the DOJ for $29.75 million. The price of Semler Scientific stock fell by 9.88% after the settlement announcement. Investors who purchased or acquired SMLR securities between March 10, 2021, and April 15, 2025, may be eligible to participate in the class action.
A class action lawsuit has been filed against Semler Scientific, Inc. (NASDAQ: SMLR) for allegedly failing to disclose investigations into violations of the False Claims Act. The lawsuit, filed by Rosen Law Firm, claims that Semler Scientific did not disclose a material investigation by the United States Department of Justice (DOJ) into violations of the False Claims Act, while discussing possible violations in hypothetical terms [1]. The company revealed the investigation in February 2025 and later settled with the DOJ for $29.75 million, excluding attorney fees [2]. The price of Semler Scientific stock fell by 9.88% after the settlement announcement.The class action lawsuit seeks to recover damages for investors who purchased or acquired SMLR securities between March 10, 2021, and April 15, 2025. According to the lawsuit, Semler Scientific made false and/or misleading statements and/or failed to disclose the DOJ investigation, which caused investors to suffer damages [1]. The lawsuit alleges that Semler Scientific's public statements were materially false and/or misleading at all relevant times.
Investors who wish to join the class action can visit the Rosen Law Firm's website or contact Phillip Kim, Esq. at 866-767-3653 or via email at case@rosenlegal.com [1]. The deadline to serve as a lead plaintiff is October 28, 2025.
The lawsuit comes as Semler Scientific, a company that develops and markets technology products and services for evaluating and treating chronic diseases, faces scrutiny over its disclosures and potential violations of the False Claims Act. The settlement with the DOJ and the subsequent stock price decline highlight the potential impact of such investigations on investor confidence and stock performance.
References:
[1] https://www.morningstar.com/news/business-wire/20250829361356/equity-alert-rosen-law-firm-files-securities-class-action-lawsuit-on-behalf-of-semler-scientific-inc-investors-smlr
[2] https://www.prnewswire.com/news-releases/investor-alert-robbins-llp-informs-investors-that-a-class-action-lawsuit-has-been-filed-against-semler-scientific-inc-302542298.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet